Four GIST patients have entered this Phase 1 trial of PI3K inhibitor SF1126. Preliminary results presented show that three had stable disease lasting from eight to 20 weeks. Additionally, it was reported that so far SF1126 has been well-tolerated and that there have been no clinically significant changes reported in glucose or insulin levels.This is important since PI3K inhibitors can have off-target effects on glucose metabolism.

This data is preliminary since the study is ongoing and still accepting patients. This trial would be a good choice for patients failing imatinib and sunitinib and in need of alternatives to off-label options. Chiorean also expressed interest in a Phase 2 study of this drug in GIST.

Abstract #: 2558

Abstract 2558, E. Gabriela Chiorean, MD, Indiana University Simon Cancer Center, Indianapolis, IN

Written by Jim Hughes